Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19

Lung-infiltrating macrophages create a marked inflammatory milieu in a subset of patients with COVID-19 by producing a cytokine storm, which correlates with increased lethality. However, these macrophages are largely not infected by SARS-CoV-2, so the mechanism underlying their activation in the lung is unclear. Type I interferons (IFN-I) contribute to protecting the host against SARS-CoV-2 but may also have some deleterious effect, and the source of IFN-I in the lungs of infected patients is not well defined. Plasmacytoid dendritic cells (pDCs), a key cell type involved in antiviral responses, can produce IFN-I in response to SARS-CoV-2. We observed the infiltration of pDCs in the lungs of SARS-CoV-2–infected patients, which correlated with strong IFN-I signaling in lung macrophages. In patients with severe COVID-19, lung macrophages expressed a robust inflammatory signature, which correlated with persistent IFN-I signaling at the single-cell level. Hence, we observed the uncoupling in the kinetics of the infiltration of pDCs in the lungs and the associated IFN-I signature, with the cytokine storm in macrophages. We observed that pDCs were the dominant IFN-α–producing cells in response to the virus in the blood, whereas macrophages produced IFN-α only when in physical contact with infected epithelial cells. We also showed that IFN-α produced by pDCs, after the sensing of SARS-CoV-2 by TLR7, mediated changes in macrophages at both transcriptional and epigenetic levels, which favored their hyperactivation by environmental stimuli. Together, these data indicate that the priming of macrophages can result from the response by pDCs to SARS-CoV-2, leading to macrophage activation in patients with severe COVID-19. Description The priming of macrophages by SARS-CoV-2-infected pDCs provokes an inflammatory response to microbial components in patient lungs. Editor’s Summary: pDCs are at the eye of the storm In severe COVID-19, macrophages induce cytokine storms, which can lead to poor patient outcomes. However, macrophages are not directly infected by SARS-CoV-2, so how this cytokine storm is induced remains unclear. Here, Laurent et al. used COVID-19 patient databases and cell culture to identify that the macrophage-induced cytokine storm was linked to IFN-I signaling in patient lungs. Plasmacytoid dendritic cells (pDCs) were the main producers of IFN-I, because they were directly infected with SARS-CoV-2, which triggered TLR7 activation. This IFN-I made macrophages more responsive to environmental stimuli, thus triggering the production of multiple cytokines. Thus, the authors present a mechanism whereby pDCs are infected by SARS-CoV-2, subsequently producing IFN-I, and stimulating a macrophage-mediated cytokine storm during SARS-CoV-2 infection.

[1]  L. Ivashkiv,et al.  CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes , 2022, Nature Communications.

[2]  L. Ivashkiv,et al.  Chemokines form nanoparticles with DNA and can superinduce TLR-driven immune inflammation , 2022, The Journal of experimental medicine.

[3]  Shondra M. Pruett-Miller,et al.  ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection , 2022, Science Immunology.

[4]  O. Elemento,et al.  Inflammatory responses in the placenta upon SARS-CoV-2 infection late in pregnancy , 2022, iScience.

[5]  J. Lieberman,et al.  Inflammasome activation in infected macrophages drives COVID-19 pathology , 2021, Nature.

[6]  M. Merad,et al.  The immunology and immunopathology of COVID-19 , 2022, Science.

[7]  L. Kristensen,et al.  TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection , 2022, The EMBO journal.

[8]  Si Ming Man,et al.  Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway , 2022, Immunity.

[9]  Vivek V. Thacker,et al.  The cGAS–STING pathway drives type I IFN immunopathology in COVID-19 , 2022, Nature.

[10]  S. Sugita,et al.  Extensive mucosal sloughing of the small intestine and colon in a patient with severe COVID‐19 , 2021, DEN open.

[11]  F. Voltarelli,et al.  The relationship between COVID‐19 viral load and disease severity: A systematic review , 2021, Immunity, inflammation and disease.

[12]  A. Tall,et al.  Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein , 2021, Scientific Reports.

[13]  Fabian J Theis,et al.  SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis , 2021, Cell.

[14]  O. Elemento,et al.  The NF-κB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication , 2021, Journal of virology.

[15]  R. Nussbaum,et al.  X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19 , 2021, Science immunology.

[16]  Mark S. Anderson,et al.  Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths , 2021, Science Immunology.

[17]  J. Casanova,et al.  Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs , 2021, The Journal of experimental medicine.

[18]  Jianguo Wu,et al.  SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation , 2021, Nature Communications.

[19]  Michael A. Smith,et al.  Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus , 2021, Science Translational Medicine.

[20]  L. Dölken,et al.  Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned , 2021, Viruses.

[21]  J. Schultze Deutsche COVID-19 Omics Initiative (DeCOI) , 2021, BIOspektrum.

[22]  Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity. , 2021, Nature cell biology.

[23]  Timothy L. Tickle,et al.  COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets , 2021, Nature.

[24]  André F. Rendeiro,et al.  A molecular single-cell lung atlas of lethal COVID-19 , 2021, Nature.

[25]  E. Coccia,et al.  Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection , 2021, bioRxiv.

[26]  C. Garlanda,et al.  SARS-CoV-2–associated ssRNAs activate inflammation and immunity via TLR7/8 , 2021, bioRxiv.

[27]  Yufeng Shen,et al.  Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells , 2021, Science Immunology.

[28]  André F. Rendeiro,et al.  The spatial landscape of lung pathology during COVID-19 progression , 2021, Nature.

[29]  J. Casanova,et al.  Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia. , 2021, Comptes rendus biologies.

[30]  F. Bazzoli,et al.  Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study , 2021, BMJ open gastroenterology.

[31]  J. Casanova,et al.  SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4 , 2021, The Journal of experimental medicine.

[32]  A. Maghazachi,et al.  Chemokines and chemokine receptors during COVID-19 infection , 2021, Computational and Structural Biotechnology Journal.

[33]  Cameron R. Wolfe,et al.  Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.

[34]  S. Perlman,et al.  SARS-CoV-2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells. , 2020, The Journal of infectious diseases.

[35]  P. Nigrovic COVID-19 cytokine storm: what is in a name? , 2020, Annals of the Rheumatic Diseases.

[36]  N. Alajez,et al.  Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19 , 2020, Cells.

[37]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[38]  J. Soriano,et al.  COVID-19 severity associates with pulmonary redistribution of CD1c+ DC and inflammatory transitional and nonclassical monocytes. , 2020, The Journal of clinical investigation.

[39]  Madeleine K. D. Scott,et al.  Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.

[40]  A. Iwasaki,et al.  Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, The Journal of experimental medicine.

[41]  Eric Song,et al.  Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[42]  T. Woodruff,et al.  COVID-19: Complement, Coagulation, and Collateral Damage , 2020, The Journal of Immunology.

[43]  Vineet D. Menachery,et al.  Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures , 2020, Journal of Virology.

[44]  Y. Marie,et al.  Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity , 2020, Nature Cell Biology.

[45]  G. Gao,et al.  Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients , 2020, Immunity.

[46]  Zhihua Zheng,et al.  Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients , 2020, Cell Host & Microbe.

[47]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[48]  C. Dooms,et al.  Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages , 2020, Cell Research.

[49]  A. Chauhan,et al.  COVID‐19: A collision of complement, coagulation and inflammatory pathways , 2020, Journal of Thrombosis and Haemostasis.

[50]  Pratik Sinha,et al.  Is a "Cytokine Storm" Relevant to COVID-19? , 2020, JAMA internal medicine.

[51]  Roland Eils,et al.  COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.

[52]  S. Heyman,et al.  The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe? , 2020, Frontiers in Immunology.

[53]  Eric Song,et al.  Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, bioRxiv.

[54]  G. Remuzzi,et al.  The case of complement activation in COVID-19 multiorgan impact , 2020, Kidney International.

[55]  Lin Cheng,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[56]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[57]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[58]  Mandeep R. Mehra,et al.  COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal , 2020, The Journal of Heart and Lung Transplantation.

[59]  C. Mummery,et al.  Generation and Functional Characterization of Monocytes and Macrophages Derived from Human Induced Pluripotent Stem Cells , 2020, Current protocols in stem cell biology.

[60]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[61]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[62]  F. Barrat,et al.  Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types? , 2019, Current opinion in rheumatology.

[63]  David K. Meyerholz,et al.  IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. , 2019, The Journal of clinical investigation.

[64]  L. Su,et al.  A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection. , 2019, The Journal of experimental medicine.

[65]  P. Auluck,et al.  Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus , 2019, The Journal of clinical investigation.

[66]  B. Reizis Plasmacytoid Dendritic Cells: Development, Regulation, and Function , 2019, Immunity.

[67]  Eugenia G. Giannopoulou,et al.  Type I IFNs and TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation , 2017, Nature Immunology.

[68]  Taeg S. Kim,et al.  Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial Cells , 2017, PLoS pathogens.

[69]  Meredith O'Keeffe,et al.  Plasmacytoid dendritic cells are short-lived: reappraising the influence of migration, genetic factors and activation on estimation of lifespan , 2016, Scientific Reports.

[70]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[71]  R. König,et al.  High Secretion of Interferons by Human Plasmacytoid Dendritic Cells upon Recognition of Middle East Respiratory Syndrome Coronavirus , 2015, Journal of Virology.

[72]  Eugenia G. Giannopoulou,et al.  Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling. , 2013, Immunity.

[73]  L. Ivashkiv,et al.  Regulation of type I interferon responses , 2013, Nature Reviews Immunology.

[74]  W. Reith,et al.  Plasmacytoid dendritic cells control T-cell response to chronic viral infection , 2012, Proceedings of the National Academy of Sciences.

[75]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[76]  P. Giresi,et al.  Using formaldehyde-assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA , 2012, Nature Protocols.

[77]  Sung Whan Cho,et al.  Alveolar Macrophages Are Indispensable for Controlling Influenza Viruses in Lungs of Pigs , 2008, Journal of Virology.

[78]  R. Coffman,et al.  PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation , 2008, The Journal of experimental medicine.

[79]  S. Akira,et al.  Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon , 2007, Blood.

[80]  David E. Swayne,et al.  Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus , 2006, Nature.

[81]  R. Coffman,et al.  Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation , 2006, The Journal of experimental medicine.

[82]  W. Cao,et al.  Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. , 2006, Blood.

[83]  C. Sousa Faculty Opinions recommendation of Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. , 2005 .

[84]  A. Al-ghonaium,et al.  Human TLR-7-, -8-, and -9-Mediated Induction of IFN-α/β and -λ Is IRAK-4 Dependent and Redundant for Protective Immunity to Viruses , 2005, Immunity.

[85]  S. Akira,et al.  Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[86]  J. Mascola,et al.  Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells , 2005, The Journal of experimental medicine.

[87]  F. Gheyas,et al.  Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. , 2001, Blood.

[88]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.